Haloperidol and Capsaicin Show More Promise Than Standard Anti-Nausea Drugs for CHS

Traditional antiemetics often fail for cannabinoid hyperemesis syndrome, but haloperidol and topical capsaicin have shown promise, alongside the essential step of cannabis cessation.

Smith, Shemyia A et al.·Cureus·2025·Moderate EvidenceReview
RTHC-07685ReviewModerate Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Standard antiemetics like ondansetron often fail to alleviate CHS symptoms. Haloperidol and topical capsaicin have shown more promise in reducing symptoms. Cannabis cessation remains essential for resolution. The challenge of predicting who will develop CHS and reaching those resistant to stopping cannabis remains a pressing research need.

Key Numbers

Standard antiemetics: often ineffective. Haloperidol: shows promise. Topical capsaicin: shows promise. Cannabis cessation: essential for resolution.

How They Did This

Narrative review exploring current and emerging treatments for CHS, including diagnosis challenges, treatment strategies, and research gaps.

Why This Research Matters

CHS is increasingly common as cannabis use rises, and its symptoms overlap with other GI disorders, leading to misdiagnosis and frequent ED visits. Knowing which treatments actually work can reduce unnecessary testing and improve patient outcomes.

The Bigger Picture

As cannabis use increases, CHS recognition and management become more important for emergency medicine. The inability to predict who will develop CHS means clinicians must be prepared to diagnose and manage it in any heavy cannabis user.

What This Study Doesn't Tell Us

Narrative review without systematic search methodology or quality assessment. Treatment evidence is based largely on case reports and small series. Cannot determine treatment effect sizes or compare treatments quantitatively.

Questions This Raises

  • ?Can biomarkers predict who will develop CHS?
  • ?How can interventions reach CHS patients who are resistant to cannabis cessation?

Trust & Context

Key Stat:
Evidence Grade:
Synthesizes current clinical knowledge from multiple sources, but narrative format without systematic methodology limits to moderate.
Study Age:
Contemporary review of CHS management literature.
Original Title:
Unraveling the Enigma of Cannabinoid Hyperemesis Syndrome: A Narrative Review of Diagnosis and Management.
Published In:
Cureus, 17(8), e90961 (2025)
Database ID:
RTHC-07685

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

What is cannabinoid hyperemesis syndrome?

CHS is a condition in chronic cannabis users causing severe, recurring nausea and vomiting that standard anti-nausea medications typically cannot relieve. It resolves with cannabis cessation.

Why don't regular anti-nausea drugs work for CHS?

The mechanism of CHS differs from typical nausea. Cannabis paradoxically disrupts the gut-brain axis in ways that standard antiemetics like ondansetron do not address. Haloperidol and capsaicin target different pathways.

Read More on RethinkTHC

Cite This Study

RTHC-07685·https://rethinkthc.com/research/RTHC-07685

APA

Smith, Shemyia A; Safwat, Mayar A; Piper, Brian J; Addison, Maame A. (2025). Unraveling the Enigma of Cannabinoid Hyperemesis Syndrome: A Narrative Review of Diagnosis and Management.. Cureus, 17(8), e90961. https://doi.org/10.7759/cureus.90961

MLA

Smith, Shemyia A, et al. "Unraveling the Enigma of Cannabinoid Hyperemesis Syndrome: A Narrative Review of Diagnosis and Management.." Cureus, 2025. https://doi.org/10.7759/cureus.90961

RethinkTHC

RethinkTHC Research Database. "Unraveling the Enigma of Cannabinoid Hyperemesis Syndrome: A..." RTHC-07685. Retrieved from https://rethinkthc.com/research/smith-2025-unraveling-the-enigma-of

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.